Hydroxychloroquine Market to Reach $2.86 Billion by 2028 Amidst Rising Demand for Autoimmune Disease Treatments [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
The global hydroxychloroquine market has shown a robust increase and is projected to continue its growth trajectory, moving from an impressive $2.07 billion in 2023 to an estimated value of $2.86 billion by 2028, expanding at a compound annual growth rate (CAGR) of 6.6%. This growth is supported by the increasing need for effective malaria treatments and the drug's applications in autoimmune diseases management. The growth can be traced back to the growing global demand for combination therapies and personalized medicine, alongside enhancements in healthcare access and governmental funding initiatives. Hydroxychloroquine's pivotal role in managing malaria, rheumatoid arthritis, lupus, and the exploration of its benefits for COVID-19 treatment, has led to this sizeable market expansion. The prevalence of autoimmune diseases such as rheumatoid arthritis is anticipated to stimulate market growth further. With the CDC reporting a rising number of arthritis cases in the United States
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Indian drugmaker Lupin misses quarterly profit estimates as costs rise [Reuters]Reuters
- Global Migraine Drugs Market Report 2024, By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants), By Route of Administration (Oral, Injectable) and By End-User [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.Business Wire
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Nestlé signs India venture with pharma group Dr Reddy's [Yahoo! Finance]Yahoo! Finance
RDY
Earnings
- 1/31/24 - Beat
RDY
Sec Filings
- 5/3/24 - Form 6-K
- 4/30/24 - Form 6-K
- 4/25/24 - Form 6-K
- RDY's page on the SEC website